Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-12-04

AUTHORS

Panpan Liu, Zhijun Huang, Mingzhu Yin, Chun Liu, Xiang Chen, Pinhua Pan, Yehong Kuang

ABSTRACT

ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). More... »

PAGES

999

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8

DOI

http://dx.doi.org/10.1186/s13063-020-04925-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1133099688

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33276811


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimalarials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "COVID-19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Case-Control Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "China", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chloroquine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-17", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lopinavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribavirin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ritonavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "SARS-CoV-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Safety", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Th17 Cells", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Panpan", 
        "id": "sg:person.0773546447.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773546447.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huang", 
        "givenName": "Zhijun", 
        "id": "sg:person.01165066554.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165066554.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yin", 
        "givenName": "Mingzhu", 
        "id": "sg:person.01266357307.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Chun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Gerontology Center of Xiangya Hospital, Central South University, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
            "Gerontology Center of Xiangya Hospital, Central South University, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Xiang", 
        "id": "sg:person.016317172774.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016317172774.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452223.0", 
          "name": [
            "The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pan", 
        "givenName": "Pinhua", 
        "id": "sg:person.0741230344.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741230344.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China", 
            "Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China", 
            "Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuang", 
        "givenName": "Yehong", 
        "id": "sg:person.01354636543.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354636543.89"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-12-04", 
    "datePublishedReg": "2020-12-04", 
    "description": "ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (\u201cTaltz\u201d) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (\u03b1-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13063-020-04925-8", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8875581", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8339084", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8351885", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "efficacy of ixekizumab", 
      "CT severity score", 
      "antiviral therapy", 
      "Central South University", 
      "Xiangya Hospital", 
      "treatment course", 
      "severity score", 
      "study protocol", 
      "COVID-19", 
      "registration number", 
      "acute respiratory distress syndrome", 
      "Chinese Clinical Trial Registry", 
      "South University", 
      "Interventional Trials guidelines", 
      "second treatment course", 
      "respiratory distress syndrome", 
      "Clinical Trials Registry", 
      "Third Xiangya Hospital", 
      "TRIAL REGISTRATION NUMBER", 
      "pro-inflammatory cytokines", 
      "Standard Protocol Items", 
      "Nanjing Medical University", 
      "parallel group design", 
      "human monoclonal antibody", 
      "main efficacy indicators", 
      "global public health event", 
      "full protocol", 
      "Th17 cells", 
      "Trials Register", 
      "distress syndrome", 
      "organ injury", 
      "interleukin-17A", 
      "primary outcome", 
      "Trials Registry", 
      "antiviral treatment", 
      "Controlled Trials", 
      "open trial", 
      "intensive care", 
      "TRIAL REGISTRATION", 
      "Trials website", 
      "Trials guidelines", 
      "severe infections", 
      "public health events", 
      "immune response", 
      "pilot trial", 
      "ixekizumab", 
      "Protocol Items", 
      "group 2", 
      "patients", 
      "group 1", 
      "CT results", 
      "efficacy indicators", 
      "Medical University", 
      "monoclonal antibodies", 
      "health events", 
      "therapy", 
      "like changes", 
      "trials", 
      "efficacy", 
      "hospital", 
      "independent research teams", 
      "days", 
      "treatment", 
      "scores", 
      "safety", 
      "two-center", 
      "structured summary", 
      "group", 
      "group design", 
      "severe epidemics", 
      "ParticipantsPatients", 
      "interleukin", 
      "chemokines", 
      "cytokines", 
      "registry", 
      "syndrome", 
      "injury", 
      "infection", 
      "overactivation", 
      "recruitment", 
      "protocol", 
      "antibodies", 
      "care", 
      "course", 
      "intervention", 
      "outcomes", 
      "epidemic", 
      "randomization", 
      "research team", 
      "summary", 
      "Register", 
      "stage", 
      "subjects", 
      "date", 
      "guidelines", 
      "data collection", 
      "cells", 
      "changes", 
      "release", 
      "response", 
      "dissemination", 
      "number", 
      "levels", 
      "recommendations", 
      "discharge", 
      "second stage", 
      "center", 
      "team", 
      "events", 
      "pilot", 
      "University", 
      "first stage", 
      "indicators", 
      "items", 
      "samples", 
      "registration", 
      "key elements", 
      "end", 
      "length", 
      "results", 
      "collection", 
      "accordance", 
      "files", 
      "websites", 
      "additional files", 
      "interest", 
      "materials", 
      "China", 
      "system", 
      "design", 
      "name", 
      "experiments", 
      "formatting", 
      "letter", 
      "elements", 
      "random systems"
    ], 
    "name": "Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial", 
    "pagination": "999", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1133099688"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13063-020-04925-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33276811"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13063-020-04925-8", 
      "https://app.dimensions.ai/details/publication/pub.1133099688"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:46", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_838.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13063-020-04925-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13063-020-04925-8'


 

This table displays all metadata directly associated to this object as RDF triples.

339 TRIPLES      20 PREDICATES      182 URIs      174 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13063-020-04925-8 schema:about N0166d87948484e16884c9aadd0a009ee
2 N07b08f5792ed46c598b7fa1614d6c4bb
3 N07f90a22bb214b169252a4380b1b166f
4 N1ff6b3904aa74c75b6e27c414ec6b453
5 N4fdb48da61c1432fbee8bdf941196491
6 N5a09bf9d8ac54953b14966546c34ba09
7 N5bb5a2ac8e914b8a9e129e282418094e
8 N5ce6d2fbf6634e4dad14afce9a4f4015
9 N5d90497ddace4e7bb543dfa44cc48400
10 N5ff7e2e443394af9b9dc22e85aa9a757
11 N7012e24160df4714b98309fa0c07b832
12 N70f1e7d5e8914cbc96cdaf0fc3b0a875
13 N77d9c8af4a86472db1eba36fc07fdaeb
14 N807bc1c84a5b4559b62fdc965f47323c
15 N81aa23d7f2cb47eebc316ed9c5403ec9
16 N8a7f3f439fae40c29a93cfbc146fe345
17 Na256b85575d24b2fa2522b8c2939b3b5
18 Naa46e5a11f674d478d6f07ccf9fe37a6
19 Ncbcda26ee98a48d1b40c65672dca7665
20 Nf216914d63e74b008dd3440c9625d9f0
21 Nfb5f8199b6584e31876f72f52bb6f5b2
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author Nae9837785f2b46df85943ef7f41c990e
25 schema:datePublished 2020-12-04
26 schema:datePublishedReg 2020-12-04
27 schema:description ObjectivesA severe epidemic of COVID-19 has broken out in China and has become a major global public health event. We focus on the Acute Respiratory Distress Syndrome (ARDS)-like changes and overactivation of Th17 cells (these produce cytokines) in patients with COVID-19. We aim to explore the safety and efficacy of ixekizumab (an injectable drug for the treatment of autoimmune diseases) to prevent organ injury caused by the immune response to COVID-19. Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.Trial designThe experiment is divided into two stages. In the first stage, the open trial, 3 patients with COVID-19 are treated with ixekizumab, and the safety and efficacy are observed for 7 days. In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. This is a two-center, open-label, randomized controlled pilot trial with 2-arm parallel group design (1:1 ratio).ParticipantsPatients with COVID-19 aged 18-75 with increased Interleukin (IL)-6 levels will be enrolled, but patients with severe infections requiring intensive care will be excluded. The trial will be undertaken in two centers. The first stage is carried out in Xiangya Hospital of Central South University, and the second stage is carried out simultaneously in the Third Xiangya Hospital of Central South University.Intervention and comparatorIn the first stage, three subjects are given ixekizumab (“Taltz”) (80 mg/ml, 160 mg as a single hypodermic injection) and antiviral therapy (α-interferon (administer 5 million U by aerosol inhalation twice daily), lopinavir/ritonavir (administer 100mg by mouth twice daily, for the course of therapy no more than 10 days), chloroquine (administer 500mg by mouth twice daily, for the course of therapy no more than 10 days), ribavirin (administer 500mg by intravenous injection two to three times a day, for the course of therapy no more than 10 days), or arbidol (administer 200mg by mouth three times a day, for the course of therapy no more than 10 days), but not more than 3 types). The treatment course of the first stage is 7 days.In the second stage, 40 randomized patients will receive the following treatments--Group 1: ixekizumab (80 mg/ml, 160 mg as a single hypodermic injection) with antiviral therapy (the same scheme as in the first stage); Group 2: antiviral therapy alone (the same scheme as in the first stage). The length of the second treatment course is 14 days.Main outcomesThe primary outcome is a change in pulmonary CT severity score (an imaging tool for assessing COVID-19, which scores on the basis of all abnormal areas involved). Pulmonary CT severity score is assessed on the 7th day, 14th day, or at discharge.RandomisationIn the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days. The eLite random system of Nanjing Medical University is used for randomization.Blinding (masking)The main efficacy indicator, the CT results, will be evaluated by the third-party blinded and independent research team.Numbers to be randomised (sample size)In the second stage, 40 patients with COVID-19 are randomly divided into two groups at 1:1 for 14 days.Trial StatusTrial registration number is ChiCTR2000030703 (version 1.7 as of March 19, 2020). The recruitment is ongoing, and the date recruitment was initiated in June 2020. The anticipated date of the end of data collection is June 2021.Trial registrationThe name of the trial register is the Chinese Clinical Trial Registry. The trial registration number is ChiCTR2000030703 (http://www.chictr.org.cn/). The date of trial registration is 10 March 2020.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N15d3b785866b464e93f175eb6e2d863d
31 N7224cfc8a67a474da5fc826d40dc9f76
32 sg:journal.1297400
33 schema:keywords COVID-19
34 CT results
35 CT severity score
36 Central South University
37 China
38 Chinese Clinical Trial Registry
39 Clinical Trials Registry
40 Controlled Trials
41 Interventional Trials guidelines
42 Medical University
43 Nanjing Medical University
44 ParticipantsPatients
45 Protocol Items
46 Register
47 South University
48 Standard Protocol Items
49 TRIAL REGISTRATION
50 TRIAL REGISTRATION NUMBER
51 Th17 cells
52 Third Xiangya Hospital
53 Trials Register
54 Trials Registry
55 Trials guidelines
56 Trials website
57 University
58 Xiangya Hospital
59 accordance
60 acute respiratory distress syndrome
61 additional files
62 antibodies
63 antiviral therapy
64 antiviral treatment
65 care
66 cells
67 center
68 changes
69 chemokines
70 collection
71 course
72 cytokines
73 data collection
74 date
75 days
76 design
77 discharge
78 dissemination
79 distress syndrome
80 efficacy
81 efficacy indicators
82 efficacy of ixekizumab
83 elements
84 end
85 epidemic
86 events
87 experiments
88 files
89 first stage
90 formatting
91 full protocol
92 global public health event
93 group
94 group 1
95 group 2
96 group design
97 guidelines
98 health events
99 hospital
100 human monoclonal antibody
101 immune response
102 independent research teams
103 indicators
104 infection
105 injury
106 intensive care
107 interest
108 interleukin
109 interleukin-17A
110 intervention
111 items
112 ixekizumab
113 key elements
114 length
115 letter
116 levels
117 like changes
118 main efficacy indicators
119 materials
120 monoclonal antibodies
121 name
122 number
123 open trial
124 organ injury
125 outcomes
126 overactivation
127 parallel group design
128 patients
129 pilot
130 pilot trial
131 primary outcome
132 pro-inflammatory cytokines
133 protocol
134 public health events
135 random systems
136 randomization
137 recommendations
138 recruitment
139 registration
140 registration number
141 registry
142 release
143 research team
144 respiratory distress syndrome
145 response
146 results
147 safety
148 samples
149 scores
150 second stage
151 second treatment course
152 severe epidemics
153 severe infections
154 severity score
155 stage
156 structured summary
157 study protocol
158 subjects
159 summary
160 syndrome
161 system
162 team
163 therapy
164 treatment
165 treatment course
166 trials
167 two-center
168 websites
169 schema:name Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial
170 schema:pagination 999
171 schema:productId N355f3f29c7604912ae7ecdddba810778
172 Naaac2ac09a63465fa5fae1591125344f
173 Nbddfb11c611f46e69199f3ca0ad2973d
174 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133099688
175 https://doi.org/10.1186/s13063-020-04925-8
176 schema:sdDatePublished 2022-10-01T06:46
177 schema:sdLicense https://scigraph.springernature.com/explorer/license/
178 schema:sdPublisher N3457afab54dc47d98ab10e910915f23d
179 schema:url https://doi.org/10.1186/s13063-020-04925-8
180 sgo:license sg:explorer/license/
181 sgo:sdDataset articles
182 rdf:type schema:ScholarlyArticle
183 N0166d87948484e16884c9aadd0a009ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Indoles
185 rdf:type schema:DefinedTerm
186 N07b08f5792ed46c598b7fa1614d6c4bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Adult
188 rdf:type schema:DefinedTerm
189 N07f90a22bb214b169252a4380b1b166f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Antimalarials
191 rdf:type schema:DefinedTerm
192 N15d3b785866b464e93f175eb6e2d863d schema:volumeNumber 21
193 rdf:type schema:PublicationVolume
194 N1d7098cfb2444c679f97eb3630da9686 schema:affiliation grid-institutes:grid.216417.7
195 schema:familyName Liu
196 schema:givenName Chun
197 rdf:type schema:Person
198 N1ff6b3904aa74c75b6e27c414ec6b453 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Ribavirin
200 rdf:type schema:DefinedTerm
201 N3457afab54dc47d98ab10e910915f23d schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 N355f3f29c7604912ae7ecdddba810778 schema:name pubmed_id
204 schema:value 33276811
205 rdf:type schema:PropertyValue
206 N4fdb48da61c1432fbee8bdf941196491 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Interleukin-17
208 rdf:type schema:DefinedTerm
209 N5a09bf9d8ac54953b14966546c34ba09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Treatment Outcome
211 rdf:type schema:DefinedTerm
212 N5bb5a2ac8e914b8a9e129e282418094e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Humans
214 rdf:type schema:DefinedTerm
215 N5ce6d2fbf6634e4dad14afce9a4f4015 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name SARS-CoV-2
217 rdf:type schema:DefinedTerm
218 N5d90497ddace4e7bb543dfa44cc48400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Aged
220 rdf:type schema:DefinedTerm
221 N5ff7e2e443394af9b9dc22e85aa9a757 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Antibodies, Monoclonal, Humanized
223 rdf:type schema:DefinedTerm
224 N66babf6adacc4b8091469ae9a552c55f rdf:first sg:person.01354636543.89
225 rdf:rest rdf:nil
226 N7012e24160df4714b98309fa0c07b832 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Lopinavir
228 rdf:type schema:DefinedTerm
229 N70f1e7d5e8914cbc96cdaf0fc3b0a875 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Ritonavir
231 rdf:type schema:DefinedTerm
232 N7224cfc8a67a474da5fc826d40dc9f76 schema:issueNumber 1
233 rdf:type schema:PublicationIssue
234 N77d9c8af4a86472db1eba36fc07fdaeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Middle Aged
236 rdf:type schema:DefinedTerm
237 N780e27826cad4e59aa52c37f955c3fb6 rdf:first sg:person.016317172774.87
238 rdf:rest Nad39c1fa8b0b4eed97b32789bdc07ab4
239 N807bc1c84a5b4559b62fdc965f47323c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Th17 Cells
241 rdf:type schema:DefinedTerm
242 N81aa23d7f2cb47eebc316ed9c5403ec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
243 schema:name COVID-19
244 rdf:type schema:DefinedTerm
245 N84355882c4ec429c9b6917e396c3c9d6 rdf:first sg:person.01165066554.34
246 rdf:rest Nda378e16b3fb4f788e623f6739e7fa6a
247 N8a7f3f439fae40c29a93cfbc146fe345 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
248 schema:name Drug Therapy, Combination
249 rdf:type schema:DefinedTerm
250 Na256b85575d24b2fa2522b8c2939b3b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
251 schema:name Safety
252 rdf:type schema:DefinedTerm
253 Naa46e5a11f674d478d6f07ccf9fe37a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
254 schema:name Antiviral Agents
255 rdf:type schema:DefinedTerm
256 Naaac2ac09a63465fa5fae1591125344f schema:name doi
257 schema:value 10.1186/s13063-020-04925-8
258 rdf:type schema:PropertyValue
259 Nad39c1fa8b0b4eed97b32789bdc07ab4 rdf:first sg:person.0741230344.37
260 rdf:rest N66babf6adacc4b8091469ae9a552c55f
261 Nae9837785f2b46df85943ef7f41c990e rdf:first sg:person.0773546447.61
262 rdf:rest N84355882c4ec429c9b6917e396c3c9d6
263 Nbd03678c8bea4df1b3bbc642ee03cff6 rdf:first N1d7098cfb2444c679f97eb3630da9686
264 rdf:rest N780e27826cad4e59aa52c37f955c3fb6
265 Nbddfb11c611f46e69199f3ca0ad2973d schema:name dimensions_id
266 schema:value pub.1133099688
267 rdf:type schema:PropertyValue
268 Ncbcda26ee98a48d1b40c65672dca7665 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
269 schema:name Case-Control Studies
270 rdf:type schema:DefinedTerm
271 Nda378e16b3fb4f788e623f6739e7fa6a rdf:first sg:person.01266357307.80
272 rdf:rest Nbd03678c8bea4df1b3bbc642ee03cff6
273 Nf216914d63e74b008dd3440c9625d9f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
274 schema:name Chloroquine
275 rdf:type schema:DefinedTerm
276 Nfb5f8199b6584e31876f72f52bb6f5b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
277 schema:name China
278 rdf:type schema:DefinedTerm
279 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
280 schema:name Medical and Health Sciences
281 rdf:type schema:DefinedTerm
282 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
283 schema:name Clinical Sciences
284 rdf:type schema:DefinedTerm
285 sg:grant.8339084 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
286 rdf:type schema:MonetaryGrant
287 sg:grant.8351885 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
288 rdf:type schema:MonetaryGrant
289 sg:grant.8875581 http://pending.schema.org/fundedItem sg:pub.10.1186/s13063-020-04925-8
290 rdf:type schema:MonetaryGrant
291 sg:journal.1297400 schema:issn 1468-6708
292 1745-6215
293 schema:name Trials
294 schema:publisher Springer Nature
295 rdf:type schema:Periodical
296 sg:person.01165066554.34 schema:affiliation grid-institutes:grid.216417.7
297 schema:familyName Huang
298 schema:givenName Zhijun
299 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165066554.34
300 rdf:type schema:Person
301 sg:person.01266357307.80 schema:affiliation grid-institutes:grid.216417.7
302 schema:familyName Yin
303 schema:givenName Mingzhu
304 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80
305 rdf:type schema:Person
306 sg:person.01354636543.89 schema:affiliation grid-institutes:grid.216417.7
307 schema:familyName Kuang
308 schema:givenName Yehong
309 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354636543.89
310 rdf:type schema:Person
311 sg:person.016317172774.87 schema:affiliation grid-institutes:grid.216417.7
312 schema:familyName Chen
313 schema:givenName Xiang
314 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016317172774.87
315 rdf:type schema:Person
316 sg:person.0741230344.37 schema:affiliation grid-institutes:grid.452223.0
317 schema:familyName Pan
318 schema:givenName Pinhua
319 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741230344.37
320 rdf:type schema:Person
321 sg:person.0773546447.61 schema:affiliation grid-institutes:grid.216417.7
322 schema:familyName Liu
323 schema:givenName Panpan
324 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773546447.61
325 rdf:type schema:Person
326 grid-institutes:grid.216417.7 schema:alternateName Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
327 Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China
328 Gerontology Center of Xiangya Hospital, Central South University, Changsha, China
329 Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
330 schema:name Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
331 Department of Respiratory and Critical Care Medicine, The Third Xiangya Hospital, Central South University, Changsha, China
332 Gerontology Center of Xiangya Hospital, Central South University, Changsha, China
333 Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
334 Hunan Key Laboratory of Skin Cancer and Psoriasis, Changsha, China
335 The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China
336 rdf:type schema:Organization
337 grid-institutes:grid.452223.0 schema:alternateName The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
338 schema:name The Respiratory Department, Xiangya Hospital, Central South University, 87 XiangYa Road, 410008, Changsha, Hunan, China
339 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...